Sucralfate in Dogs and Cats: Dosing, Timing, and What the Evidence Supports

Bottom line

Sucralfate is not an acid suppressant and should not be reasoned about as one: it is a locally acting mucosal barrier agent that requires acid to activate. The 2018 ACVIM consensus statement on gastrointestinal protectants grades the evidence supporting sucralfate for preventing or treating esophageal injury as weak, concludes that proton pump inhibitors are superior to sucralfate for gastroduodenal ulceration and erosion (GUE), and states that no evidence indicates that combining sucralfate with either a PPI or an H2-receptor antagonist for GUE is beneficial or indicated [1]. Its most defensible use is adjunctive treatment of esophagitis, where the argument is mucosal comfort rather than faster healing. The best-quantified thing sucralfate reliably does in dogs is not heal ulcers but impair the absorption of co-administered oral drugs, which makes the dosing schedule the part of the prescription most worth getting right.

Drug facts

Class and mechanism. Sucralfate is a complex salt of sucrose octasulfate and aluminum hydroxide [1]. In an acidic environment it becomes viscous and partially dissociates into sucrose sulfate and aluminum hydroxide; the sucrose sulfate moiety is an anion and binds electrostatically with the positively charged proteins in damaged mucosa, where protein concentration is high from the exudate of an ulcer or from damaged cells [1]. The Merck Veterinary Manual describes the same process as sucrose octasulfate polymerizing into a viscous, sticky substance that binds to ulcerated mucosa, preventing back-diffusion of hydrogen ions, inactivating pepsin and adsorbing bile acid, with a secondary increase in mucosal prostaglandin synthesis [2]. Sucralfate also interferes with pepsin by preventing pepsin digestion of protein substrates, by binding pepsin, or by acting as a diffusion barrier [1].

This is the pharmacological point clinicians most often miss. Acid suppressants raise intragastric pH systemically; sucralfate does nothing to acid secretion and instead requires acid to convert into its active, adherent form at the site of injury.

Absorption. Sucralfate is only minimally absorbed from the gastrointestinal tract, and the small amounts of sulfated disaccharide that are absorbed are excreted primarily in the urine; its effect is local rather than systemic [3]. In human subjects, sucralfate at ulcer-therapy doses inhibits pepsin activity in gastric juice by 32%, and there are approximately 14 to 16 mEq of acid-neutralizing capacity per 1 g dose [3].

Formulations. CARAFATE oral suspension contains 1 g of sucralfate per 10 mL [3]; 1 g tablets also exist but are a poor choice in dogs (see administration, below).

Label status. The prescribing information cited here is a human label [3], and the Merck Veterinary Manual states directly that dosage regimens are extrapolated from human dosages [2]. Use in dogs and cats is therefore extra-label and should be documented as such.

Dosing. The Merck Veterinary Manual professional edition lists dogs at 500-1000 mg, PO, q 6-8 h and cats at 250-500 mg, PO, q 8-12 h [2]. The 2024 feline evidence review lists sucralfate for cats at 0.25 g PO q8h, dissolved in 5 ml water [4].

Cautions. Animals in renal failure may have increased aluminum absorption [2]. The human label warns that aluminum accumulation and toxicity, including aluminum osteodystrophy, osteomalacia and encephalopathy, have been described in patients with renal impairment, and that sucralfate should be used with caution in patients with chronic renal failure [3].

What the 2018 ACVIM consensus actually recommends

The consensus statement is unusually direct, and it is worth reading what it does and does not say. Its consensus opinion on sucralfate for esophagitis or gastroduodenal ulceration comprises these positions [1]:

• There is weak evidence in experimental animals and humans to support the use of sucralfate for preventing or treating esophageal injury.
• There is moderate evidence that sucralfate may have analgesic effects in people post-tonsillectomy, but no studies have evaluated the analgesic properties of sucralfate in people or animals with esophagitis.
• No evidence supports either a benefit or an interaction when sucralfate is administered concurrently with H2RAs or PPIs.
• When administered to dogs (and perhaps cats), intact tablets may not fully disintegrate and may not be as effective as a liquid suspension.
• No evidence indicates that combining sucralfate with either a PPI or an H2RA for treatment of GUE is beneficial or indicated.
• Proton pump inhibitors are superior to sucralfate for management of GUE.

Note what the panel declines to do. It does not recommend sucralfate for GUE, and it does not recommend against co-administration with a PPI either; on the co-administration question it explicitly reports an absence of evidence in both directions rather than a verdict. Its broader position on ulceration is that PPIs are superior to H2RAs, sucralfate and misoprostol for most causes of GUE in people and should be considered standard of care for the medical treatment of GUE in dogs and cats [1]. Reading that as an endorsement of adding sucralfate on top is a misreading.

The acid-dependence and co-administration timing problem

Sucralfate needs acid, and clinicians routinely prescribe it alongside a drug whose entire purpose is removing acid. The folklore conclusion is that a PPI abolishes sucralfate's effect and the two must therefore be spaced apart. The evidence is thinner and more interesting than that.

The mechanistic premise holds up. Tolbert and Stubbs note that while experimental studies show sucralfate exerting a cytoprotective effect on healthy esophageal mucosa before acid-induced esophagitis, there are no studies indicating that sucralfate exhibits the same protective mechanisms when applied after esophageal injury has already occurred, and they attribute this to the fact that sucralfate requires an acid environment to exert its protective mechanism [4]. The ACVIM consensus reports the same phenomenon from the reflux literature: sucralfate deposited in a nonacidified esophagus was rapidly cleared and poorly timed to provide protection against reflux injury [1].

The clinical premise does not follow as cleanly. The ACVIM panel's position is that no evidence supports either a benefit or an interaction when sucralfate is given concurrently with an H2RA or a PPI [1], and it further notes that in controlled human studies no significant benefit was observed from combining sucralfate with an H2RA compared with either drug alone, whether for acute duodenal ulcer, ulcer maintenance, stress bleeding or reflux esophagitis [1]. In other words, on the specific question of whether acid suppression blunts sucralfate, the consensus reports an absence of evidence on both sides rather than a finding in either direction.

Tolbert and Stubbs do give a timing instruction, recommending that sucralfate be administered as a slurry with the timing organized so as to separate sucralfate from other medications that are dependent on gastric acidity, giving PPIs and tetracyclines as examples [4]. That recommendation is mechanistically motivated rather than outcome-validated, and the same review advises that if administration 2 hours before or after other medications is not feasible, or owner compliance is expected to falter, PPI therapy should be preferred over sucralfate for gastroduodenal ulceration [4].

Synthesising these honestly: separating sucralfate from a PPI is defensible and low-cost, but the more useful question is prior to timing. If the case genuinely needs acid suppression, the consensus supports a PPI and does not support adding sucralfate to it for GUE. If the case is esophagitis, sucralfate has a stronger argument as an adjunct, and separating the doses costs nothing. What is not defensible is adding sucralfate to a PPI reflexively and then treating the timing question as the hard part.

Efficacy: where the veterinary evidence actually is

Esophagitis. This is sucralfate's best indication and the evidence is still largely extrapolated. In rabbits, esophagitis induced by acid and pepsin was prevented by sucralfate, and in a separate study cats pretreated with liquid sucralfate before acid infusion were protected against esophagitis [1]. Both are prophylactic models in healthy mucosa, which is precisely the gap Tolbert and Stubbs flag for treatment after injury has occurred [4]. In humans, sucralfate was as effective as an alginate/antacid preparation for healing of esophagitis and symptomatic improvement, and ranitidine, cimetidine and sucralfate had equal efficacy for treating reflux esophagitis, although higher-grade esophagitis did not heal as well as lower-grade disease [1]. Against placebo, conflicting data have been obtained in human patients with reflux esophagitis [1]. Esophageal retention is a real limitation: in a study of technetium-labeled sucralfate, the drug was retained within the esophagus for 3 hours in fewer than 50% of patients with reflux esophagitis [1].

Despite that, Tolbert and Stubbs would more strongly recommend sucralfate in patients with esophagitis than in gastroduodenal ulceration, on the basis that extrapolation from human medicine indicates sucralfate does not significantly impact the healing rate but appears to exert a soothing effect on irritated mucosa, increasing patient comfort earlier than placebo [4]. Worth pairing with attention to the underlying reflux; see the metoclopramide hub for the prokinetic side of that question.

Gastric and duodenal ulceration. In an ex vivo model of acid-induced mucosal bleeding in dogs, sucralfate was effective in promoting repair of gastric mucosal tissue when applied at the time of or shortly after acid-induced injury [1]. Tolbert and Stubbs note sucralfate performed better than placebo in accelerating healing of gastroduodenal ulceration, but that at the time of writing there was no study comparing PPI monotherapy with sucralfate or with combination therapy [4]. The Merck Veterinary Manual is blunter: although sucralfate is frequently administered to small animals as prevention or treatment for GUE, there is little evidence of its efficacy in animals, and sucralfate is inferior to PPIs in the treatment of GUE [2]. For the acid-suppression side of this decision, see the omeprazole and gastroprotectants hub.

NSAID and glucocorticoid-associated injury. The clearest positive signal is not in dogs or cats: in foals, sucralfate had a protective effect on oral, esophageal and gastric ulcers associated with IV administration of high-dose phenylbutazone [1]. For steroid-associated injury, the ACVIM panel reviewed reports of GI complications in dogs with spinal cord disease and spinal surgery and concluded that no evidence from clinical reports of dogs or from research studies shows that gastroprotectant drugs are beneficial for preventing or decreasing GI complications from high doses of corticosteroids, noting that the gastroprotectants used in those reports were sucralfate, misoprostol and H2RAs [1]. Its consensus opinion is that in these cases there is no convincing evidence that gastroprotectant drugs are beneficial [1].

Drug interactions and the separation interval

This is the part of the sucralfate file with the strongest, most quantified evidence, and it happens to be evidence of harm rather than benefit.

The human CARAFATE label reports that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption of single doses of cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline and theophylline [3]. The mechanism appears to be nonsystemic, presumably from sucralfate binding the concomitant agent in the gastrointestinal tract [3]. The ACVIM consensus lists substantially decreased bioavailability with ciprofloxacin, theophylline, tetracycline, doxycycline, minocycline, phenytoin and digoxin [1].

Direction matters. Give the interacting drug first and sucralfate afterwards. Per the human label, in all cases studied to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin and ranitidine), dosing the concomitant medication 2 hours before sucralfate eliminated the interaction [3]. The ACVIM consensus reports that the bioavailability of digoxin, tetracycline, doxycycline and phenytoin was not decreased when they were given 2 hours before sucralfate [1].

Three canine crossover studies quantify this properly:

Doxycycline. In five dogs, AUC and maximum plasma concentration were significantly lower (P < 0.001) with concurrent sucralfate suspension (AUC 7.2 h·μg/mL, CMAX 0.43 μg/mL) than with doxycycline alone (AUC 36.0 h·μg/mL, CMAX 2.53 μg/mL), giving a relative bioavailability of 20% [5]. Delaying sucralfate suspension by 2 h after doxycycline raised relative bioavailability to 74% [5]. Notably, no interaction was seen when sucralfate was given as a tablet, and sucralfate tablet fragments were frequently observed in some dogs' feces [5].

Minocycline. Oral minocycline (300 mg) and sucralfate suspension (1 g) were given to five greyhounds [6]. Minocycline alone produced a CMAX of 1.15 μg/mL and an AUC of 8.0 h·μg/mL [6]. Concurrent sucralfate significantly reduced these (P < 0.05) to a CMAX of 0.33 μg/mL and an AUC of 3.0 h·μg/mL, whereas delaying sucralfate by 2 h gave a CMAX of 0.97 μg/mL and an AUC of 10.3 h·μg/mL [6]. Delaying sucralfate by 2 h did not decrease oral minocycline absorption, but concurrent administration significantly decreased it [6].

Fluoroquinolones. In five healthy Greyhounds, mean relative bioavailability for ciprofloxacin with concurrent sucralfate was 48% (range 8-143%) compared with ciprofloxacin alone, improving to 87% (range 37-333%) when sucralfate was delayed by 2 hours [7]. By contrast, relative bioavailability for enrofloxacin with concurrent sucralfate was 104% (94-115%), and the authors concluded that no significant difference in bioavailability was documented for enrofloxacin with sucralfate [7]. That distinction matters in practice, because enrofloxacin is the approved fluoroquinolone in most small-animal settings, and the blanket formulary warning against fluoroquinolone co-administration appears not to apply to it in fed Greyhounds, though the authors called for investigation in fasted dogs and clinical cases before generalizing [7].

Read the 2-hour interval as mitigation, not as a clean threshold. Recovery to a relative bioavailability of 74% for doxycycline [5] and 87% for ciprofloxacin [7] is a large improvement, but neither is restoration to baseline, and where drug exposure is critical the safer move is to reconsider whether the sucralfate is needed at all. Note also the width of the ciprofloxacin ranges [7]: individual dogs varied enormously, so a population mean understates the risk in any single patient. For dosing considerations with another commonly co-prescribed GI drug, see the metronidazole hub.

Adverse effects, and the aluminum question

Sucralfate is genuinely well tolerated. The ACVIM consensus describes it as a relatively safe compound with minimal adverse effects [1]. In human clinical studies involving over 2700 patients treated with sucralfate, adverse effects were reported in 129 (4.7%), with constipation the most frequent complaint at 2% [3]. The ACVIM consensus reports constipation, caused by the aluminum hydroxide component, as one of the most common adverse effects, typically occurring in 1%-3% of human patients taking the drug, with xerostomia, nausea, vomiting, headache, urticaria and rashes in 0-5% of patients [1].

Two safety points deserve more weight than their headline rarity suggests.

Aluminum in renal impairment. Aluminum absorption during sucralfate treatment is comparable to that during treatment with aluminum hydroxide, and the ACVIM consensus advises caution with long-term treatment in patients with renal insufficiency to avoid aluminum intoxication [1]. The human label adds that patients with chronic renal failure or on dialysis have impaired excretion of absorbed aluminum, that aluminum does not cross dialysis membranes because it is bound to albumin and transferrin, and that aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy) have been described in patients with renal impairment [3]. Concomitant use with other aluminum-containing products, such as aluminum-containing antacids, may increase total body aluminum burden [3].

The feline CKD signal. The most directly relevant small-animal safety data come from a study that was not even testing gastroprotection. Quimby and Lappin administered a 500 mg sucralfate slurry orally q 8 hr for 2 wk to normal cats and to normophosphatemic cats with CKD, evaluating it as a phosphate binder [8]. In normal cats, vomiting occurred after 14.7% of administrations [8]. Of the five normophosphatemic CKD cats treated, three experienced clinical decompensation including vomiting, anorexia, constipation and increased azotemia, and the study was discontinued because of side effects and the apparent lack of efficacy [8]. Tolbert and Stubbs translate this into practice by advising that sucralfate be given only once the animal is well hydrated, with caution in cats with CKD because of concern for constipation, hypovolemia and consequent exacerbation of azotemia [4].

Bezoar formation is a rare but documented event, reported mainly in patients with underlying conditions predisposing to bezoars, such as delayed gastric emptying, or receiving concomitant enteral tube feedings [3] — a combination that describes a meaningful slice of hospitalised veterinary patients.

Administration in practice

Use the suspension. The ACVIM consensus states that when administered to dogs (and perhaps cats), intact tablets may not fully disintegrate and may not be as effective as a liquid suspension [1], and that the lack of interaction with sucralfate tablets suggests they do not adequately disintegrate in dogs and should be administered as a suspension rather than an intact tablet [1]. The underlying canine study saw tablet fragments in feces [5]. If only tablets are available, crushing and slurrying in water reproduces the intended dosage form; Tolbert and Stubbs specify a slurry, and for cats a 0.25 g dose dissolved in 5 ml water [4].

Expect compliance friction. Many cats do not accept the chalky taste of sucralfate or the need for frequent administration, and where compliance is expected to falter or the 2-hour separation from other medications is impractical, Tolbert and Stubbs would recommend PPI therapy over sucralfate for gastroduodenal ulceration [4]. With q6-8h dosing in dogs [2] plus a 2-hour separation from other oral drugs, a realistic medication schedule is worth sketching before dispensing rather than after.

Confirm the indication first. Sucralfate sits inside a class that is demonstrably overprescribed. In a review of gastroprotectant dispensation at a tertiary referral center, 67 of 110 cats (60.9%) were prescribed a gastroprotectant without an appropriate indication, with sucralfate given in 18/110 (16.4%); among the 35 cases where therapy was indicated, the medication chosen or dosage administered was considered suboptimal in 16 (45.7%) [9]. The most common reason for an inappropriate prescription was acute kidney injury, in 26/67 (38.8%) [9] — which is also the population in which the aluminum and dehydration concerns bite hardest.

Where sucralfate sits against the alternatives

For confirmed or strongly suspected gastroduodenal ulceration, a PPI is the better-supported choice: the ACVIM consensus places PPIs as superior to H2RAs, sucralfate and misoprostol for most causes of GUE and as standard of care for medical treatment of GUE in dogs and cats [1], and Merck concurs that sucralfate is inferior to PPIs for GUE [2]. See the omeprazole and gastroprotectants hub for dosing and tapering, and the famotidine hub for where an H2RA still earns a place and the tachyphylaxis problem that limits it.

For esophagitis, sucralfate has its strongest case, as an adjunct aimed at mucosal comfort alongside acid suppression and correction of the underlying reflux [4]. For NSAID prophylaxis specifically, misoprostol rather than sucralfate is the agent with supporting experimental canine data in the consensus [1].

Writing in 2024, Tolbert and Stubbs recorded that there was no study comparing PPI monotherapy with sucralfate or with combination therapy for gastroduodenal ulceration [4] — the trial that would most change practice.

Frequently Asked Questions

What is the sucralfate dose for dogs and cats? The Merck Veterinary Manual professional edition lists 500-1000 mg, PO, q 6-8 h for dogs and 250-500 mg, PO, q 8-12 h for cats, and notes explicitly that these dosage regimens are extrapolated from human dosages rather than derived from canine or feline trials. The 2024 feline evidence review by Tolbert and Stubbs lists a flat 0.25 g PO q8h dissolved in 5 ml of water for cats. Sucralfate is a human-label product, so every use in dogs and cats is extra-label.

Does a proton pump inhibitor stop sucralfate from working? No published evidence establishes that it does. The 2018 ACVIM consensus statement is explicit that no evidence supports either a benefit or an interaction when sucralfate is given concurrently with H2-receptor antagonists or PPIs. The mechanistic worry is real, because sucralfate needs an acid environment to activate, and Tolbert and Stubbs attribute the failure of sucralfate to protect already-injured esophageal mucosa to exactly that acid requirement. But the consensus stops short of a timing rule for PPIs specifically, and it states the combination is neither shown beneficial nor indicated for GUE, while stopping short of documenting a pharmacologic interaction. The practical implication is less about spacing the two drugs and more about asking whether the sucralfate is earning its place in the protocol at all.

How long should sucralfate be separated from other oral drugs? Give the other drug first and the sucralfate two hours later, not the reverse. That direction is what the human CARAFATE label tested: dosing the concomitant medication 2 hours before sucralfate eliminated the interaction for cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin and ranitidine. The ACVIM consensus reports the same direction for digoxin, tetracycline, doxycycline and phenytoin. Note that the canine data show recovery rather than perfect elimination: relative bioavailability was restored to 74% for doxycycline and 87% for ciprofloxacin when sucralfate was delayed by 2 hours, so a two-hour gap mitigates the interaction but is not a guarantee for a narrow-therapeutic-index drug.

Should I dispense sucralfate as a tablet or a suspension? Suspension, in almost every case. KuKanich and KuKanich found no interaction at all between sucralfate tablets and doxycycline in dogs and frequently observed intact sucralfate tablet fragments in the dogs' feces, which tells you the tablet is passing through without disintegrating. The ACVIM consensus draws the same conclusion, stating that intact tablets may not fully disintegrate in dogs and may not be as effective as a liquid suspension. A tablet that does not disintegrate cannot form the mucosal barrier that is the entire point of the drug.

Is sucralfate safe in cats with chronic kidney disease? Use it cautiously and not reflexively. Quimby and Lappin gave a 500 mg sucralfate slurry orally q 8 hr for 2 wk to cats and found that three of five normophosphatemic cats with CKD experienced clinical decompensation including vomiting, anorexia, constipation and increased azotemia, and the study was discontinued because of side effects and apparent lack of efficacy. In normal cats, vomiting occurred after 14.7% of administrations. Separately, the human CARAFATE label warns that aluminum accumulation and toxicity have been described in patients with renal impairment and that sucralfate should be used with caution in chronic renal failure. Tolbert and Stubbs advise giving sucralfate only once the animal is well hydrated.

Does sucralfate actually heal gastric ulcers in dogs and cats? No canine or feline trial has compared PPI monotherapy with sucralfate or combination therapy, and the Merck Veterinary Manual notes there is little evidence of its efficacy in animals. The ACVIM consensus concludes that proton pump inhibitors are superior to sucralfate for management of gastroduodenal ulceration and erosion. Tolbert and Stubbs note that sucralfate outperformed placebo for accelerating healing of gastroduodenal ulceration, while recording in 2024 that the head-to-head comparison had not been done. If a dog or cat has confirmed or strongly suspected ulceration, a PPI is the better-supported first choice.

Is sucralfate worth using for esophagitis? This is its strongest indication, though the benefit is more likely comfort than healing. Tolbert and Stubbs state that, in contrast to gastroduodenal ulceration, they would more strongly recommend sucralfate in patients with esophagitis, and note that extrapolating from human medicine, sucralfate does not significantly change the healing rate but appears to soothe irritated mucosa and improve comfort earlier than placebo. The ACVIM consensus grades the underlying evidence as weak and points out that no controlled study has evaluated the analgesic properties of sucralfate in people or animals with esophagitis, so the comfort rationale is plausible but not proven. Sucralfate is an adjunct here, not a substitute for acid suppression and for correcting the underlying cause of reflux.